Table 3. Reconstructed haplotypes and the association with risk of developing late skin toxicity (telangiectasia) with score ⩾2 after radiotherapy.

Gene	Haplotype	Frequency	ORa	95% CI
All patients
TP53	GA1	0.71	1
	GA2	0.03	1.02	0.29–3.63
	CA1	0.16	1.20	0.79–1.82
	CA2b	0.11	1.97	1.11–3.52
Patients without acute toxicity during radiotherapy c
TP53	GA1	0.71	1
	GA2	0.02	0.68	0.13–3.60
	CA1	0.16	1.15	0.71–1.85
	CA2	0.12	2.78	1.44–5.37
Patients with acute toxicity during radiotherapy
TP53	GA1	0.71	1
	GA2	0.04	1.10	0.09–13.41
	CA1	0.17	1.47	0.52–4.17
	CA2	0.09	0.52	0.11–2.53
All patients
XRCC1	CCGG	0.41	1
	TCGG	0.12	1.15	0.66–2.00
	TCGA	0.36	0.78	0.53–1.15
	TTGG	0.05	0.51	0.21–1.24
	Rared	0.07	0.56	0.26–1.20
XPD	GA	0.56	1
	GC	0.09	1.25	0.64–2.46
	AA	0.06	1.14	0.55–2.38
	AC	0.29	1.09	0.74–1.62

CI=confidence interval; NTD=normalised total dose; OR=odds ratio.

^aAdjusted for NTD, age the time of late toxicities evaluation, time since radiotherapy (months), clinic, acute skin toxicity, high blood pressure, allergy, pack-years (never, <20, ⩾20), skin type (always/moderate/seldom sunburn), clinic, marital status (single/divorced/widowed, married/partner).

^bA2 allele carries a duplication of 16 bp in intron 3.

^cP=0.06 for effect heterogeneity according to occurrence of acute skin toxicity.

^dComposed of haplotypes with frequencies below 5%.